So one of the presentations given at the recent EAU meeting in Stockholm was an update, by Dr. Jonas Hugosson, at a median 13 years of follow-up, from the European Randomized Study of Screening for Prostate Cancer (ERSPC) — and there is some good news, but maybe not enough to get carried away by … yet. READ MORE …

Genetic information is starting to become a key factor in the testing of selected men for their risk for certain types of prostate cancer, and for the potential value of certain therapeutic agents in the treatment of prostate cancer in selected individuals. … READ MORE …

According to a newly published, prospective study in the Journal of Urology, a research team at the Mayo Clinic has confirmed prior reports (based on retrospective data) that a baseline PSA in men aged between 40 and 49 years can be used to categorize men into low and higher prostate cancer risk groups. … READ MORE …